- San Diego, CA
- Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
- Roger Hawley, Jonathan M. Rigby
- Pharmaceutical, Health Care, Biotechnology
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.
We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
Funding Rounds (6) - $167.06MUpdate
Current Team (7)Update
|May 26, 2016||PRNewswire UK All - Needle Free Drug Delivery Devices Market to Reach US$13.1 Billion by 2023; Led by Needle-free Technologies: TMR|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - Risky Business: Late Stage vs Early Stage Biotech|
|Dec 2, 2015||PRNewswire All - Global Injection Pump Market 2016-2021 Outlook Report|
|Dec 2, 2015||PRNewswire UK All - Global Injection Pump Market 2016-2021 Outlook Report|
|Nov 3, 2015||PRNewswire UK All - Global Prefilled Syringes Market (3rd Edition), 2015 - 2025|
|Oct 26, 2015||PRNewswire All - DURECT Corporation Announces Third Quarter 2015 Financial Results and Update of Programs|
|Oct 13, 2015||ir.zogenix.com - News Release - Investor Relations - Zogenix|
|Jul 31, 2015||PRNewswire UK All - Syringes and Needles Market Products Pipeline Review 2015 Report|
12671 High Bluff Dr
San Diego, CA 92130